Dr. Samuel Mehr
Claim this profileNebraska Cancer Specialists
Studies Neuroendocrine Tumors
Studies Uterine Tumors
8 reported clinical trials
15 drugs studied
Area of expertise
1Neuroendocrine Tumors
Stage IV
Stage III
2Uterine Tumors
Stage IV
Stage III
Affiliated Hospitals
Clinical Trials Samuel Mehr is currently running
[225Ac]-FPI-2068
for Cancer
This is a first-in-human, Phase 1, non-randomized, multicenter, open-label clinical study designed to investigate the safety, tolerability, dosimetry, biodistribution, and pharmacokinetics (PK) of \[225Ac\]-FPI-2068, \[111In\]-FPI-2107, and FPI-2053 in metastatic and/or recurrent solid tumors (HNSCC, NSCLC, mCRC, PDAC).
Recruiting1 award Phase 16 criteria
Radioligand Therapy
for Prostate Cancer
The purpose of this study is to evaluate the change in the expression of treatment targets on the surface of tumor cells (Prostate Specific Membrane Antigen (PSMA), Somatostatin Receptor 2 (SSTR2), and Gastrin Releasing Peptide Receptor (GRPR) between the start and after the completion of radioligand therapy (RLT). Study will use radioligand imaging (RLI) to determine predominantly expressed target on the surface of tumor cells. Based on predominant expression of target, corresponding RLT targeting PSMA, SSTR2, or GRPR RLT will be given for up to 6 cycles every 6 weeks as intravenous (i.v.) injection in participants with metastatic neuroendocrine prostate cancer (mNEPC).
Recruiting1 award Phase 14 criteria
More about Samuel Mehr
Clinical Trial Related1 year of experience running clinical trials · Led 8 trials as a Principal Investigator · 7 Active Clinical TrialsTreatments Samuel Mehr has experience with
- Lutathera
- Long-acting Octreotide
- High Dose Long-acting Octreotide
- RYZ101
- [212Pb]VMT01
- [212Pb]VMT-α-NET
Breakdown of trials Samuel Mehr has run
Neuroendocrine Tumors
Uterine Tumors
Pancreatic Cancer
Prostate Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Samuel Mehr specialize in?
Samuel Mehr focuses on Neuroendocrine Tumors and Uterine Tumors. In particular, much of their work with Neuroendocrine Tumors has involved Stage IV patients, or patients who are Stage III.
Is Samuel Mehr currently recruiting for clinical trials?
Yes, Samuel Mehr is currently recruiting for 7 clinical trials in Omaha Nebraska. If you're interested in participating, you should apply.
Are there any treatments that Samuel Mehr has studied deeply?
Yes, Samuel Mehr has studied treatments such as Lutathera, long-acting octreotide, high dose long-acting octreotide.
What is the best way to schedule an appointment with Samuel Mehr?
Apply for one of the trials that Samuel Mehr is conducting.
What is the office address of Samuel Mehr?
The office of Samuel Mehr is located at: Nebraska Cancer Specialists, Omaha, Nebraska 68130 United States. This is the address for their practice at the Nebraska Cancer Specialists.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.